Curated News
By: NewsRamp Editorial Staff
September 09, 2026
Kairos Pharma CEO to Present at H.C. Wainwright Conference
TLDR
- Kairos Pharma presents at H.C. Wainwright conference, offering investors a chance to see CEO John Yu's vision for ENV-105, a potential game-changer in oncology.
- CEO John Yu will present Kairos Pharma's corporate overview at H.C. Wainwright conference, detailing ENV-105's mechanism targeting CD105 to reverse drug resistance in cancer.
- Kairos Pharma's ENV-105 aims to restore standard therapies' effectiveness for multiple cancers, potentially improving survival and quality of life for patients.
- Kairos Pharma presents at prestigious conference, spotlighting ENV-105 antibody that targets CD105 to combat cancer resistance, a novel approach in oncology.
Impact - Why it Matters
This news matters because Kairos Pharma's presentation at a major investment conference highlights its progress in developing ENV-105, a potential breakthrough in overcoming cancer drug resistance. For patients, this could mean more effective treatments for various cancers; for investors, it signals a promising opportunity in the oncology space. The company's focus on targeting CD105 addresses a critical unmet need in cancer therapy, making this announcement significant for both the medical community and those interested in biotech investments.
Summary
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, taking place Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation provides an opportunity for investors to learn about Kairos Pharma's innovative approach to oncology therapeutics, which leverages structural biology to address drug resistance and immune suppression in cancer.
Kairos Pharma's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. The company is based in Los Angeles, California, and is dedicated to advancing treatments that could significantly improve patient outcomes.
The news was disseminated by InvestorWire, a specialized communications platform that provides advanced wire-grade press release syndication for private and public companies. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers a range of services including article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more details on the announcement, visit the full press release at https://ibn.fm/NrBQD, and for the latest updates on KAPA, check the company's newsroom at https://ibn.fm/KAPA.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma CEO to Present at H.C. Wainwright Conference
